# **HINOON**

#### **CY22 Result Review: BUY Stance Maintained**



Equity Research | Pharmaceuticals | Thursday, 23 February, 2023

HINOON has announced its CY22 result where it posted a profit after tax of Rs2.42bn (EPS: Rs57.71) as compared to a profit after tax of Rs1.81bn (EPS: Rs43.17) in the same period last year, up by 33.7% YoY. We note that this growth is attributed to the increase in volumetric sales along with a hike in prices.

The company has posted a revenue of Rs15.82bn against Rs13.00bn in SPLY, recording a growth of 21.7% YoY. The gross margin has slightly increased to 50.8% as compared to 49.3% during SPLY.

SG&A expenses have been increased by 16.6% to Rs4.60bn as compared to Rs3.95bn during SPLY. Lastly, effective taxation has slightly decreased to 27.7% as compared to 23.8% during SPLY.

HINOON is currently trading at CY23E PE of 7.70x. Furthermore, it is also trading at a CY23E PB of 2.02x which offers a discount of 42% relative to its historical 3-year average of 3.49x. We maintain our **BUY** stance on the scrip with a DCF based Dec-23 TP of Rs560 which provides an upside potential of 16%. Further, the scrip provides a dividend yield of 4%, which makes the cumulative return 20%.

Rupees' millions	4QCY22	4QCY21	YoY	CY22	CY21	YoY
Net Sales	3,784	3,421	10.6% ▲	15,816	13,001	21.7% ▲
Cost of Sales	1,713	1,755	2.4% ▼	7,786	6,585	18.2% ▲
Gross Profit	2,071	1,666	24.3% ▲	8,030	6,416	25.2% ▲
SG&A Expenses	1,095	946	15.7% ▲	4,603	3,947	16.6% ▲
Other Expenses	59	66	10.9% ▼	321	214	50.0% ▲
Operating Profit	914	653	40.1% ▲	3,095	2,245	37.8% ▲
Other Income	81	48	68.1% ▲	305	163	87.5% ▲
Finance Cost	22	19	18.9% ▲	54	36	51.4% ▲
Profit Before Taxation	973	682	42.6% ▲	3,346	2,372	41.0% ▲
Taxation	287	101	183.6% ▲	928	564	64.6% ▲
Profit After Taxation	686	581	18.0% ▲	2,417	1,808	33.7% ▲
Earnings Per Share	16.37	13.87	18.0% ▲	57.71	43.17	33.7% ▲
Dividend	20.00	20.00	-	20.00	20.00	-
Bonus	10%	0%		10%	0.00	
	Closing	Date: April 22,	2023 to April 2	19, 2023		
Gross Margin	54.7%	48.7%	6.0% ▲	50.8%	49.3%	1.4% ▲
SG&A Expenses to Sales	28.9%	27.7%	1.3% ▲	29.1%	30.4%	1.3% ▼
Other Expenses to Sales	1.5%	1.9%	0.4% ▼	2.0%	1.6%	0.4% ▲
Other Income to Sales	2.1%	1.4%	0.7% ▲	1.9%	1.3%	0.7% ▲
Effective Taxation	29.5%	14.8%	14.7% ▲	27.7%	23.8%	4.0% ▲
Net Margin	18.1%	17.0%	1.1% ▲	15.3%	13.9%	1.4% ▲

Source: ACPL Research, Company Financials



bbasi and Company (Pvt.) Ltd.

## **Financial Projections**

Rupees' millions	CY20A	CY21A	CY22A	CY23E	CY24E	CY25E	CY26E
Net sales	10,698	13,001	15,816	17,089	19,288	21,770	24,572
Cost of sale	5,576	6,585	7,786	8,659	9,773	11,031	12,450
Gross profit	5,121	6,416	8,030	8,430	9,515	10,739	12,121
Selling and distribution	2,645	3,416	3,988	4,310	4,864	5,490	6,196
Administration expenses	448	531	615	590	666	752	849
Research and development	6	9	11	11	13	15	17
Other operating expenses	179	214	321	265	299	337	380
Operating Profit	1,842	2,245	3,095	3,254	3,673	4,145	4,679
Other operating income	104	163	305	367	414	468	528
Finance cost	24	36	54	65	70	75	80
Profit before taxation	1,922	2,372	3,346	3,556	4,017	4,538	5,127
Taxation	501	564	928	929	1,049	1,185	1,339
Profit after taxation	1,421	1,808	2,417	2,627	2,968	3,353	3,788
EPS	33.92	43.17	57.71	62.73	70.86	80.05	90.43

Source: ACPL Research, Company Financials

### **Horizontal Analysis**

	CY20A	CY21A	CY22A	CY23E	CY24E	CY25E	CY26E
Net sales	20.6%	18.2%	21.5%	21.7%	8.1%	12.9%	12.9%
Cost of sale	22.1%	14.1%	18.1%	18.2%	11.2%	12.9%	12.9%
Gross profit	18.9%	23.1%	25.3%	25.2%	5.0%	12.9%	12.9%
Selling and distribution	17.8%	10.8%	29.1%	16.7%	8.1%	12.9%	12.9%
Administration expenses	5.8%	21.2%	18.5%	15.8%	-3.9%	12.9%	12.9%
Research and development	31.9%	27.2%	36.0%	22.6%	8.1%	12.9%	12.9%
Other operating expenses	35.6%	49.0%	19.6%	50.0%	-17.7%	12.9%	12.9%
Operating Profit	24.1%	43.9%	21.9%	37.8%	5.1%	12.9%	12.9%
Other operating income	157.9%	21.7%	56.9%	87.5%	20.4%	12.9%	12.9%
Finance cost	185.2%	0.8%	49.0%	51.4%	20.1%	7.7%	7.1%
Profit before taxation	27.0%	43.3%	23.4%	41.0%	6.3%	13.0%	13.0%
Taxation	12.0%	35.4%	12.6%	64.6%	0.0%	13.0%	13.0%
Profit after taxation	33.8%	46.3%	27.3%	33.7%	8.7%	13.0%	13.0%
EPS	33.8%	46.3%	27.3%	33.7%	8.7%	13.0%	13.0%

Source: ACPL Research, Company Financials

Abbasi and Company (Pvt.) Ltd.

## **Key Ratios**

Profitability Ratios		CY20A	CY21A	CY22A	CY23E	CY24E	CY25E	CY26E
GP Margin	%	47.87	49.35	50.77	49.33	49.33	49.33	49.33
NP Margin	%	13.28	13.91	15.28	15.37	15.39	15.40	15.42
OP Margin	%	17.22	17.27	19.57	19.04	19.04	19.04	19.04
ROE	%	31.67	31.38	29.24	26.29	24.87	23.72	22.81
ROCE	%	26.59	28.08	27.03	24.62	23.53	22.63	21.92
ROA	%	22.09	22.49	21.56	17.70	15.65	14.20	13.11
Liquidity Ratios		CY20A	CY21A	CY22A	CY23E	CY24E	CY25E	CY26E
Current	х	4.30	3.87	6.04	7.81	9.50	11.16	12.76
Acid-test	Х	3.24	3.10	3.58	3.58	3.59	3.60	3.61
Cash to current liab.	х	0.76	0.51	2.22	3.98	5.65	7.28	8.87
Activity Ratios		CY20A	CY21A	CY22A	CY23E	CY24E	CY25E	CY26E
Inventory Turnover	Х	3	3	3	3	3	3	3
Inventory Days		128	123	120	124	123	123	123
Receivables Days		12	18	16	15	15	15	15
Payables Days		36	54	42	42	42	42	42
Operating Cycle		103	86	93	97	96	96	96
Investment Ratios		CY20A	CY21A	CY22A	CY23E	CY24E	CY25E	CY26E
EPS		33.92	43.17	57.71	62.73	70.86	80.05	90.43
DPS		20.00	20.00	20.00	21.50	24.50	27.50	31.50
Div. Yield	%	4.14	4.14	4.14	4.45	5.07	5.69	6.52
Dividend Cover	х	1.70	2.16	2.89	2.92	2.89	2.91	2.87
BVPS		107.11	137.59	197.36	238.59	284.95	337.50	396.43
Payout	%	58.96	46.33	34.66	34.27	34.58	34.35	34.83
Retention	%	41.04	53.67	65.34	65.73	65.42	65.65	65.17
No. of Shares	'000	41,884	41,884	41,884	41,884	41,884	41,884	41,884
P/E		14.24	11.19	8.37	7.70	6.82	6.03	5.34
Sales per share		255.41	310.40	377.61	408.02	460.51	519.76	586.66
P/BV		4.51	3.51	2.45	2.02	1.70	1.43	1.22
Price to Sales		2.19	1.80	1.48	1.37	1.22	1.08	0.95
Gearing Ratios		CY20A	CY21A	CY22A	CY23E	CY24E	CY25E	CY26E
Debt to Equity	Х	0.11	0.06	0.04	0.04	0.03	0.02	0.02
Interest Cover	х	76.41	62.50	56.89	49.80	52.21	55.02	58.24

Source: ACPL Research, Company Financials

Abbasi and Company (Pvt.) Ltd.

This report has been prepared by Abbasi & Company (Private) Limited and is provided for information purposes only. Under no circumstances, this is to be used or considered as an offer to sell or solicitation of any offer to buy. While reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, Abbasi & Company (Private) Limited and or any of its officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report. This report is provided only for the information of professional advisers who are expected to make their own investment decisions without undue reliance on this report. Investments in capital markets are subject to market risk and Abbasi & Company (Private) Limited accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and needs of investors, who should seek further professional advice or rely upon their own judgment and acumen before making any investment. The views expressed in this report are those of Abbasi & Company (Private) Limited Research Department and do not necessarily reflect those of the company or its directors. Abbasi & Company (Private) Limited as a firm may have business relationships, including investment--banking relationships, with the companies referred to in this report. Abbasi & Company (Private) Limited does not act as a market maker in the securities of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives do not have a financial interest in the securities of the subject company to an amount exceeding 1% of the value of the securities of the subject company at the time of issuance of this report. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives are not currently serving or have served in the past three years as a director or officer of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives have not received compensation from the subject company in the previous 12 months. The subject company currently is not, or during the 12-month period preceding the date of publication or distribution of this report, was not, a client of Abbasi & Company (Private) Limited. We have not managed or co-managed a public offering or any take-over, buyback or delisting offer of securities for the subject company in the past 12 months and/or received compensation for corporate advisory services, brokerage services or underwriting services from the subject company in the past 12 months. Abbasi & Company (Private) Limited does not expect to receive or intend to seek compensation for corporate advisory services or underwriting services from the subject company in the next 3 months

All rights reserved by Abbasi & Company (Private) Limited. This report or any portion hereof may not be reproduced, distributed or published by any person for any purpose whatsoever. Nor can it be sent to a third party without prior consent of Abbasi & Company (Private) Limited. Action could be taken for unauthorized reproduction, distribution or publication

#### **VALIDITY OF THE PUBLICATION OR REPORT**

The information in this publication or report is, regardless of source, given in good faith, and may only be valid as of the stated date of this publication or report. The information may be subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company, jurisdiction or financial instruments referred to in this report. The valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report and were based upon several estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein is not to be relied upon as a representation and/or warranty by Abbasi & Company (Private) Limited and/or its other associated and affiliated companies, that:

- I. Such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- II. There is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein

#### **DEFINITION OF TERMS**

TP	Target Price	CAGR	Compound Annual Growth Rate	FCF	Free Cash Flows
FCFE	Free Cash Flows to Equity	FCFF	Free Cash Flows to Firm	DCF	Discounted Cash Flows
PE	Price to Earnings Ratio	PB	Price to Book Ratio	BVPS	Book Value Per Share
EPS	Earnings Per Share	DPS	Dividend Per Share	ROE	Return of Equity
ROA	Return on Assets	SOTP	Sum of the Parts	LDCP	Last Day Closing Price

#### **VALUATION METHODOLOGY**

To arrive at our Target Price, Abbasi & Company (Private) Limited uses different valuation methods which include:

- I. Discounted Cash Flow Model
- II. Dividend Discount Model
- III. Relative Valuation Model
- IV. Sum of Parts Valuation

#### RATINGS CRITERIA

Abbasi & Company (Private) Limited employs a three-tier ratings system to rate a stock and sector, as mentioned below, which is based upon the level of expected return for a specific stock and outlook of sector. The rating is based on the following with stated time horizon

Stock Rating	Expected Total Return
BUY	Greater than 15%
HOLD	Between -5% to 15%
SELL	Less than and equal to -5%

Sector Rating	Sector Outlook
Overweight	Positive
Market Weight	Neutral
Underweight	Negative

Ratings are updated to account for any development impacting the economy/sector/company, changes in analysts' assumptions or a combination of these factors.

### RESEARCH DISSEMINATION POLICY

Abbasi & Company (Private) Limited endeavors to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as email, fax mail etc. Nevertheless, all clients may not receive the material at the same time

#### OTHER DISCLOSURES

The research analyst is primarily involved in the preparation of this report, certifies that:

- I. The views expressed in this report accurately reflect his/her personal views about the subject company/stock /sector and economy
- II. No part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report

The Research Analyst is not and was not involved in issuing of a research report on any of the subject company's associated companies

#### RESEARCH DEPARTMENT

6 - Shadman, Lahore

Phone: (+92) 42 38302028; Ext 116, 117 Email: research@abbasiandcompany.com web: www.abbasiandcompany.com

#### **HEAD OFFICE**

6 - Shadman, Lahore

Phone: (+92) 42 38302028

Email: info@abbasiandcompany.com web: www.abbasiandcompany.com